Biltmore Family Office LLC Sells 126 Shares of Zoetis Inc. (NYSE:ZTS)

Biltmore Family Office LLC lessened its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 7.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,645 shares of the company’s stock after selling 126 shares during the period. Biltmore Family Office LLC’s holdings in Zoetis were worth $268,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also modified their holdings of ZTS. Mission Wealth Management LP boosted its holdings in shares of Zoetis by 2.0% in the fourth quarter. Mission Wealth Management LP now owns 2,938 shares of the company’s stock valued at $479,000 after buying an additional 59 shares during the period. VeraBank N.A. boosted its stake in Zoetis by 4.1% in the 4th quarter. VeraBank N.A. now owns 1,562 shares of the company’s stock worth $254,000 after purchasing an additional 62 shares during the period. HUB Investment Partners LLC raised its stake in shares of Zoetis by 4.7% in the 4th quarter. HUB Investment Partners LLC now owns 1,373 shares of the company’s stock valued at $224,000 after purchasing an additional 62 shares during the period. Procyon Advisors LLC grew its holdings in shares of Zoetis by 1.4% during the fourth quarter. Procyon Advisors LLC now owns 4,712 shares of the company’s stock worth $768,000 after buying an additional 63 shares in the last quarter. Finally, Deseret Mutual Benefit Administrators raised its position in Zoetis by 6.6% in the 4th quarter. Deseret Mutual Benefit Administrators now owns 1,045 shares of the company’s stock valued at $170,000 after buying an additional 65 shares during the last quarter. 92.80% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of brokerages have recently commented on ZTS. Piper Sandler boosted their price objective on shares of Zoetis from $200.00 to $205.00 and gave the stock an “overweight” rating in a research report on Thursday, February 27th. UBS Group assumed coverage on shares of Zoetis in a research note on Monday, December 9th. They set a “neutral” rating and a $196.00 price objective for the company. Barclays lifted their target price on Zoetis from $242.00 to $244.00 and gave the company an “overweight” rating in a research report on Friday, February 14th. Stifel Nicolaus decreased their price target on Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a research note on Tuesday, January 7th. Finally, Morgan Stanley lowered their price target on Zoetis from $243.00 to $238.00 and set an “overweight” rating on the stock in a research report on Friday, February 14th. One equities research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, Zoetis presently has an average rating of “Buy” and a consensus target price of $215.90.

Zoetis Stock Performance

NYSE ZTS opened at $163.59 on Thursday. The stock has a market cap of $73.25 billion, a PE ratio of 29.91, a P/E/G ratio of 2.78 and a beta of 0.94. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.08 and a current ratio of 1.75. The firm has a 50-day moving average of $166.20 and a 200-day moving average of $173.98. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.33.

Zoetis (NYSE:ZTS) last issued its quarterly earnings data on Thursday, February 13th. The company reported $1.40 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.37 by $0.03. The company had revenue of $2.32 billion during the quarter, compared to analysts’ expectations of $2.30 billion. Zoetis had a return on equity of 53.82% and a net margin of 26.86%. On average, sell-side analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be given a dividend of $0.50 per share. This represents a $2.00 annualized dividend and a yield of 1.22%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s payout ratio is 36.56%.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 326 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $170.00, for a total transaction of $55,420.00. Following the transaction, the executive vice president now directly owns 15,781 shares of the company’s stock, valued at approximately $2,682,770. This trade represents a 2.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Willie M. Reed sold 1,210 shares of the business’s stock in a transaction that occurred on Tuesday, March 11th. The shares were sold at an average price of $166.14, for a total value of $201,029.40. Following the completion of the sale, the director now owns 11,245 shares of the company’s stock, valued at approximately $1,868,244.30. This trade represents a 9.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 1,862 shares of company stock valued at $312,254. 0.16% of the stock is currently owned by corporate insiders.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.